Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-10-02
2007-10-02
Chernyshev, Olga N. (Department: 1649)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C424S185100, C424S184100, C530S300000, C530S326000
Reexamination Certificate
active
10821250
ABSTRACT:
A pharmaceutical composition, or pharmaceutical agent for treating Aβ amyloidosis in a patient that has at least one laminin-derived peptide or fragment thereof from the group D-A13, D-HA3G76, D-A4G82, D-A5G81, D-A5G101, D-HA3G47, D-HA3G58, D-HA3G74, D-HA3G83, D-A5G82, D-R-AG73, D-R-A13, D-R-HA3G76, D-R-A4G82, and D-R-A5G81.
REFERENCES:
Koo et al. “Amyloid β- Protein as a Substrate Interacts with Extracellular Matrix to Promote Neurite Outgrowth,” Proc. Natl. Acad. Science, vol. 90, pp. 4748-4752, May 1993.
Narindrasorsak et al. “Characterization of High Affinity Binding between Laminin and Alzheimer's Disease Amyloid Precursor Proteins,” Laboratory Investigation, vol. 67, No. 5, pp. 64-652, 1992.
Narindrasorsak et al. “An Interaction between Basement Membrane and Alzheimer Amyloid Precursor Proteins Suggests a Role in the Pathogenesis of Alzheimer's Diesease,” Laboratory Investigation, vol. 72, No. 3, pp. 272-282, 1995.
Mann. “Cerebral Amyloidosis, Ageing and Alzheimer's Disease; A Contribution From Studies on Down's Syndrome,” Neurobiology of Aging, vol. 10, pp. 397-399, 1989.
Gajdusek. “Unconventional viruses and the Origin and Disappearance of Kuru,” Science, vol. 197, No. 4307, Sep. 2, 1977.
Prusiner et al. “Purification and Structural Studies of a Major Scrapie Prion Protein,” Cell, vol. 38, 127-134, Aug. 1984.
Tateishi et al. “Gerstmann-Straussler-Scheinker Disease: Immunohistological and Experimental Studies,” Annals of Neurology, vol. 24, No. 1, Jul. 1988.
Foidart et a. “Distribution and Immunoelectron Microscopic Localization of Laminin, A Non collagenous Basement Membrane Glycoprotein,” Laboratory Investigation, vol. 42, No. 3, p. 336, 1980.
Burgeson et al. “A New Nomenclature for the Laminins,” Matrix Biology, vol. 14, pp. 209-211, 1994.
Yurchenco et al. “Laminin Polymerization in Vitro: Evidence for a two step assembly with Domain Specificity,” The Journal of Biology Chemistry, vol. 260, No. 12, pp. 7636-7644, Jun. 25, 1985.
Yurchenco et al., “Laminin Forms an Independent Network in Basement Membranes,” The Journal of Cell Biology, vol. 117, No. 5, pp. 1119-1133, Jun. 1993.
Newgreen et al. “Fibronectin in Early Avian Embroys: Synthesis and Distribution Along the Migration Pathways of Neural Crest Cells,” Cell Tissue Res. vol. 211, pp. 211-269, 1980.
Rovasio et al. “Neural Crest Cell Migration: Requirements for Exogenous Fibronectin and High Cell Density,” The Journal of Cell Biology, vol. 96, pp. 462-473, Feb. 1983.
Lander et al. “Laminin is associated with the 'nuerite outgrowth-promotion factors′ found in conditioned media,” Proc. Natl. Acad. Sci. USA, vol. 82, pp. 2183-2187, Apr. 1985.
Fraser et al. “A monclonal antibody against a laminin-heparen sulfate proeoglycan complex perturbs cranial neural crest migration in vivo,” The Journal of Cell Biology, vol. 106, pp. 1321-1329, Apr. 1988.
Kleinman et al. “Formation of a Supramolecular Complex Is Involved the Reconstitution of Basement Membrane Composets,” Biochemistry, vol. 22, pp. 4969-4974, 1983.
Engvall et al. “Mapping of Domains in Human Laminin Using Monoclonal Antibodies: Localiztion of the Neurite-promotion Site,” The Journal of Cell Biology, vol. 103, No. 6, Pt. 1, pp. 2457-2465, 1986.
Liese et al. “Laminin is induced in astrocytes of adult brain by injury,” The EMBO Journal, vol. 3, No. 3, pp. 683-686, 1984.
Terranova et al. “Role of laminin in the attachment of PAM 212 (epithelial) Cells to Basement Membrane Collagen,” Cell, vol. 22, pp. 719-726, Dec. 1980.
Rao et al. “Binding domain for laminin of type IV collagen,” Biochemical and biophysical research communications, vol. 128, No. 1, Apr. 16, 1985.
Charonis et al. “Binding of laminin to type IV collagen: A morphological study,” The Journal of Cell Biology, vol. 100, pp. 1848-1853, 1985.
Laurie et al. “Localization of Binding Sites for Laminin, Heparen Sulfate Proteoglycan and Fibronectin on Basement Membrane (Tyoe IV) Collagen,” J. Mol. Biol., vol. 189, pp. 206-216, 1986.
Riopelle et al. “Functional interactions of neuronal heparan sulphate proteoglycans with laminin,” Brain Research, vol. 525, pp. 92-100, 1990.
Battaglia et al. “Basement-membrane heparan sulfate proteoglycan binds to laminin by its heparan sulfate chains and to nidogen by sites in the protein core,” Eur. J. Biochem., vol. 208, pp. 359-366, 1992.
Sakashita et al. “Basement membrane glycoprotein laminin binds to heparin,” FEBS Letters, vol. 116, No. 2, Jul. 1980.
Del Rosso et al. “Binding of the basement-membrane glycoprotein laminin to glycosaminoglycans,” Biochem. J., vol. 199, pp. 699-704, 1981.
Skubitz et al. “Localization of three distinct heparin-hinding Domains of Laminin by Monoclonal antibodies,” The Journal of Biological Chemistry, vol. 263, No. 10, pp. 4861-4868, Apr. 5, 1988.
Hall et al. “The α1/β1and α6/β1integrin heterodimers mediate cell attachment to distinct sites on laminin,” The Journal of Cell Biology, vol. 110, pp. 2175-2184, Jun. 1990.
Goodman et al. “Multiple cell surface receptors for the short arms of laminin: α1/β1 integrin and RGD-dependent proteins mediate cell attachment only to domains III in Murine Tumor Laminin,” The Journal of Cell Biology, vol. 113, No. 4, pp. 931-941, May 1991.
Yurchenco et al. “Heparin modulation of laminin polymerization,” The Journal of Biological Chemistry, vol. 265, No. 7, pp. 3981-3991, Mar. 5, 1990.
Fox et al. “Recombinant nidogen consists of three globular domains and mediates binding of laminin to collagen type IV,” The EMBO Journal, vol. 10, No. 11, pp. 3137-3146, 1991.
Sung et al. “Cell and Heparin Binding in the Distal Long Arm of Laminin: Identification of Active and Cryptic Sites with Recombinant and Hybrid Glycoprotein,” The Journal of Cell Biology, vol. 123, No. 5, pp. 1255-1268, Dec. 1993.
Shimomura et al. “Studies on Macromolecular Components of human glomerular basement membrane and alterations in diabetes,” Diabetes. vol. 36, Mar. 1987.
Lyon et al. “Co-deposition of basement membrane components during the induction of murine splenic AA amyloid,” Laboratory Investigation, vol. 64, No. 6, p. 785, 1991.
Perlmutter et al. “Microangiopathy, the Vascular Basement Membrane and Alzheimer's Disease: A Review,” Brain Research Bulletin, vol. 24, pp. 677-686, 1990.
Murtomaki et al. “Laminin and its neurite outgrowth-promotin domain in the brain in alzheimer's disease and down's syndrome patients, ” Journal of Neuroscience Research, vol. 32, pp. 261-273, 1992.
Perlimutter et al. “Vascular basement membrane components and the lesions of Alzheimer's Disease: light and electron microscopic analyses,” Laboratory Investigation, vol. 67, No. 5, p. 643, 1992.
Narindrasorasak et al. “Characterization of high affinity binding between lanimim and Alzheimer's Disease amyloid precursor proteins,” Laboratory Investigation, vol. 67, No. 5, p. 643, 1992.
Naiki et al. “Kinetic analysis of amyloid fibril polymerization in vitro,” Laboratory Investigation, vol. 65, No. 1, p. 104, 1991.
Levine et al. “Thioflavine T interaction with synthetic Alzheimer's Disease β-amyloid peptides: detection of amyloid aggregation in solution,” Protein Science, vol. 2, pp. 404-410, 1993.
Maiki et al. “First-order kinetic model of alzheimer's β-amyloid fibril extension in vitro,” Laboratory Investigation, vol. 74, No. 2, p. 374, 1996.
Westermark et al. “Islet amyloid in type 2 human diabetes mellitus and adult diabetic ats cantains a novel putative polypeptide hormone,” American Journal of Pathology, vol. 127, No. 3, Jun.
Castillo Gerardo M.
Lake Thomas P.
Nguyen Beth P.
Snow Alan D.
Chernyshev Olga N.
Dwyer Patrick M.
LandOfFree
Small peptides for the treatment of Alzheimer's disease and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Small peptides for the treatment of Alzheimer's disease and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Small peptides for the treatment of Alzheimer's disease and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3845931